4D Molecular Therapeutics, Inc. Fair Value Adjustment of Warrants
4D Molecular Therapeutics, Inc. (FDMT) reported Fair Value Adjustment of Warrants of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value adjustment of warrants for fiscal 2025 was $0.00.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 10-K · filed 2026-03-18 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $0.00 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |